Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

Tocris Bioscience™ CG 858

Selective BRAF-V600E protein Degrader (uSMITE™)

Manufacturer:  Tocris Bioscience™ 7427/5

Catalog No. 74-275

Add to cart
This item is not returnable. View return policy



CG 858 is a selective BRAF-V600E protein Degrader (uSMITETM). CG 858 comprises the BRAF kinase inhibitor vemurafenib linked to the E3 ligase ligand Thalidomide (Cat. No. 0652). CG 858 dose-dependently degrades BRAF-V600E but not wild type BRAF, and reduces cell viability and colony formation in HT-29 and A375 cells (DC50 values are 124 nM and 500 nM, respectively). Exhibits 88% degradation at 500 nM. CG 858 also impairs melanoma cell growth.

CG 858 negative control (Cat. No. 7428) also available.



N-[[4-[3-[2,6-Difluoro-3-[(propylsulfonyl)amino]benzoyl]-1 H-pyrrolo[2,3-b]pyridin-5-yl]phenyl]methyl]-5-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1 H-isoindol-5-yl]amino]pentanamide
Active Degraders
5 mg
Safety and Handling

Safety and Handling

Recommended Storage : Store at -20°C

Product Certifications


Provide Content Correction

We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Cancel Submit